期刊
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
卷 111, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pnpbp.2020.110108
关键词
Heart rate variability; Schizophrenia; Bipolar disorder; Psychosis
资金
- Novo Nordisk Foundation [NNF16OC0019856]
- Research Council of Norway [223273, 249795]
- South-Eastern Norway Regional Health Authority [2014097, 2016083]
- European Research Council under the European Union's Horizon 2020 research and Innovation program (ERC StG) [802998]
- Norwegian South-East Health Authorities [2015078]
- Ebbe Froland foundation
- CoMorMent [847776]
Heart rate variability was significantly decreased in patients with schizophrenia and bipolar disorder, and was associated with disease severity, potentially serving as a biomarker for disease severity in SZ and BD.
While a growing literature links cardiac autonomic dysregulation to a variety of psychiatric disorders, the relationship between cardiac autonomic functioning and specific symptoms in schizophrenia (SZ) and bipolar disorder (BD) remains elusive. Thus, we investigated heart rate variability (HRV), a proxy for vagal activity, as a biological marker for symptom severity in patients with SZ and BD. HRV was calculated in 35 patients with SZ and 52 patients with BD, as well as in 149 healthy controls. In the patient groups, symptom severity and function were measured by the Positive and Negative Syndrome Scale (PANSS) and the Global Assessment of Functioning (GAF) scale. Results showed that HRV was significantly lower in both clinical groups compared to the healthy controls, with no significant HRV differences between patient groups. PANSS general psychopathology scores, GAF symptom scores, and GAF function scores showed statistically significant associations with HRV across groups. These results suggest that disease severity is associated with autonomic dysfunction and that HRV may provide a potential biomarker of disease severity in SZ and BD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据